Genprex

Monthly Archives: March 2021

Taking gene therapy to the masses with innovations in diabetes, Alzheimer’s and more

What will it take to transition gene therapy from a treatment for diseases that only affect a few hundred thousand people worldwide to Type 1 diabetes, which is estimated to affect more than 45 million?

Read More

Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting

Two Featured Presentations will Highlight Potential of TUSC2 Immunogene Therapy to Enhance Chemo-Immune Combination Treatments and Overcome Resistance to Osimertinib

Read More

Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29

Investor presentation to highlight novel gene therapies for cancer and diabetes

Read More

Genprex to Participate in Upcoming March Investor Conferences

Investor presentations to highlight novel gene therapies for cancer and diabetes

Read More